Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission

The article presents example of modeling for pharmacoeconomical-founded choice of chronic myelogenous leukemia treatment strategy related to therapeutic efficacy and economical rationality. The economic model of chronic myelogenous leukemia diagnosis and treatment with Markov chain approach was cons...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. A. Shuvaev, K. M. Abdulkadyrov, I. S. Martynkevich, M. S. Fominykh
Format:	Article
Language:	Russian
Published:	ABV-press 2015-01-01
Series:	Онкогематология
Subjects:	chronic myelogenous leukemia tyrosine kinase inhibitors imatinib nilotinib dasatinib pharmacoeconomic cost-utility generic substitution
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/119
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)

Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice
by: AG Turkina, et al.
Published: (2017-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions
by: Irena Philipova, et al.
Published: (2025-07-01)

Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study
by: Ana Maria Meireles, et al.
Published: (2025-07-01)

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
by: Rima Hajjo, et al.
Published: (2025-06-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2020-02-01)

The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
by: Mohan Bajranglal Agarwal, et al.
Published: (2024-08-01)

Priapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case report
by: T. Yu. Pavlova, et al.
Published: (2022-11-01)

Gelatinous Marrow Transformation in Chronic Myeloid Leukemia Post-Dasatinib Treatment: A Case Report with Review of Literature
by: Gayathri Kini, et al.

Cytokine profile in patients with chronic myeloid leukemia
by: T. N. Aleksandrova, et al.
Published: (2024-01-01)

PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE
by: E. I. Tarlovskaya, et al.
Published: (2015-09-01)

The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad
by: Sandip A Shah
Published: (2013-01-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

Predicting Binding Affinity of Some Imatinib Derivatives as BCR-ABL Tyrosine Kinase Inhibitors Based on Monte Carlo Optimization
by: Shahram Lotfi, et al.
Published: (2024-09-01)

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene
by: Ewelina Testoni, et al.
Published: (2016-01-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
by: Bai‐Liang He, et al.
Published: (2020-03-01)

Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia
by: D. V. Kustova, et al.
Published: (2024-09-01)

Place of Allogeneic Hematopoietic Stem Cell Transplantation in the First Complete Remission in Ph-positive Acute Lymphoblastic Leukemia in Adults
by: K. S. Afanaseva, et al.
Published: (2023-12-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2016-06-01)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
by: Jovita Martin, et al.
Published: (2011-01-01)

CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019-05-01)

Cytogenetic study of Acute myelogenous Leukemia in Erbil City-Iraqi Kurdistan Region
by: Kazhall Muhammad Sulaeman
Published: (2018-04-01)

Clinical Features and T‐Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC‐TFR Study
by: Hiroshi Ureshino, et al.
Published: (2025-08-01)

Current trends in the treatment of recurrent adenocystic cancer of the salivary glands: case report
by: O. A. Saprina, et al.
Published: (2023-03-01)

Bilateral mandibular osteonecrosis associated with imatinib monotherapy for a patient with chronic myeloid leukemia
by: Yasuharu Yajima, et al.
Published: (2025-04-01)

Pharmacoeconomic Analysis of Therapy with Generic Statin Drugs in Patients with High and Very High Cardiovascular Risk (According to the Study PRIORITY)
by: S. Yu. Martsevich, et al.
Published: (2020-11-01)

Bone Marrow and Kidney Findings at Odds: A Case Report and Review of Literature of Divergent Pathology in Chronic Myeloid Leukemia
by: Shivani Ranga, et al.

Investigation of the anti-cancer drugs imatinib and thalidomide using analytical spectroscopy (FT-IR, UV-Vis) and molecular docking simulations
by: P. Venkata Ramana, et al.
Published: (2025-07-01)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
by: Junwen Zhou, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease
by: E. I. Tarlovskaya, et al.
Published: (2016-03-01)

ECONOMIC REASONS FOR GENERIC CHOICE
by: N. P. Kutishenko, et al.
Published: (2016-01-01)

Expression profiles of miR-411 and SPRY4 as indicators of disease progression and treatment in chronic myelogenous leukemia
by: Ashkan Shabannezhad, et al.
Published: (2025-08-01)

The case of successful therapy with Nilotinib in patients with Ph-positive chronic myelogenous leukemia of chronic phase resistant to Interferon and Gleevec
by: N. A. Afanasyeva, et al.
Published: (2022-11-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Spontaneous remission of acute myeloid leukemia in children. Case series and literature review
by: V. V. Klyukhin, et al.
Published: (2024-12-01)

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01)